CNCE - コンサ―ト・ファ―マシュ―ティカルズ (Concert Pharmaceuticals Inc.)

CNCEのニュース

   Concert Pharmaceuticals Successfully Completes Open Label Trial of CTP-543 in Patients with Alopecia Areata  2019/12/19 21:05:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #Aim2TreatAlopeciaAreata--Results in the 8 mg twice-daily arm were consistent with the previously-reported 8 mg twice-daily results from the Company’s Phase 2 trial of CTP-543.
   Concert Pharmaceuticals Initiates CTP-692 Phase 2 Trial in Schizophrenia  2019/12/02 12:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert initiates Phase 2 to evaluate the safety and efficacy of CTP-692 in patients with schizophrenia who are stable on an antipsychotic medication.
   Concert Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Company Update  2019/11/07 12:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will host a conference call and webcast today to discuss third quarter financial results and provide a business update.
   Concert Pharmaceuticals to Host KOL Webcast Event Focused on CTP-692 and Schizophrenia  2019/11/06 12:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will host a conference call and webcast with Dr. Joseph Coyle on November 14, 2019, focused on CTP-692 and schizophrenia.
   Analysts Estimate Concert Pharmaceuticals (CNCE) to Report a Decline in Earnings: What to Look Out for  2019/10/31 14:35:01 Zacks Investment Research
Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Concert Pharmaceuticalsが統合失調症でCTP-692第2相試験を開始 Concert Pharmaceuticals Initiates CTP-692 Phase 2 Trial in Schizophrenia  2019/12/02 12:00:00 Business Wire
「マサチューセッツ州レキシントン-(ビジネスワイヤ)---- $ CNCE#CNCE--コンサートは、抗精神病薬で安定している統合失調症患者のCTP-692の安全性と有効性を評価するためにフェーズ2を開始します。
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert initiates Phase 2 to evaluate the safety and efficacy of CTP-692 in patients with schizophrenia who are stable on an antipsychotic medication.
   Concert Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Company Update  2019/11/07 12:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will host a conference call and webcast today to discuss third quarter financial results and provide a business update.
   Concert Pharmaceuticals to Host KOL Webcast Event Focused on CTP-692 and Schizophrenia  2019/11/06 12:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will host a conference call and webcast with Dr. Joseph Coyle on November 14, 2019, focused on CTP-692 and schizophrenia.
   Analysts Estimate Concert Pharmaceuticals (CNCE) to Report a Decline in Earnings: What to Look Out for  2019/10/31 14:35:01 Zacks Investment Research
Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Concert Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 7, 2019  2019/10/31 11:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will report its third quarter 2019 financial results on Thursday, November 7, 2019, before the U.S. financial markets open.
   Key events next week - healthcare  2019-04-18
Noteworthy events during the week of April 21 - 27 for healthcare investors. More news on: Galmed Pharmaceuticals Ltd., Horizon Pharma plc, Concert Pharmaceuticals, Inc., Healthcare stocks news, , Read more …

calendar